ÂÜÀòÂÒÂ×

Carlos Solórzano, PhD, joined Pivotal in 2019. Before joining Pivotal, Carlos was an Associate Director in the corporate strategy and business development team at Ultragenyx Pharmaceutical where he worked on competitive intelligence, as well as portfolio, commercial and BD strategy. In particular, Carlos participated in Ultragenyx’ option to acquire GeneTx (ASO for Angelman Syndrome), the expansion of Ultragenyx’ collaboration agreement with Arcturus Therapeutics (nucleic acid therapeutics including mRNA), as well as in the technology and portfolio strategy of Ultragenyx’ gene therapy platform. Prior to Ultragenyx, Carlos worked as an equity research associate at Deutsche Bank and Oppenheimer & Co. covering smid- and large-cap biotech companies. Carlos earned his PhD in Pharmacology from UC Irvine and was an NIH postdoctoral scholar at UC San Francisco where he investigated the neurobiology of pain and itch.